You are here: Industry Insights > 1

News List

2025 Q1: Oncology Business Competition Among MNCs Xiaobin
June 04, 2025
How did MNCs fare in the oncology field during Q1 of this year?
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
Top 10 Sales Volume of New Drugs of Traditional Chinese Medicine: Behind the Numbers - Only 2 Out of 29 Surpassed RMB 100 Million in Sales Xiao Yan
March 14, 2025
From 2016 - 2024, TCM new drugs made progress but lagged in sales. This article analyzes reasons and explores future directions.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
Universal CAR-T, Transaction +1 xiaobin
December 20, 2024
CAR-T therapy (chimeric antigen receptor t-cell immunotherapy) has been a favorite of the innovative drug market in recent years.
Formulation Changes and Bridging During Formulation Development – Part 1 Deepak Hegde
November 22, 2024
an outline of formulations change during development, details of the kind of Formulation changes from Phase 1 clinical study to commercialization of drug, Formulation changes Post-Approval and Commercialization.
Japanese Pharmaceutical Market & Registration Strategies – Part 1 Deepak Hegde
November 12, 2024
The article provides an outline of characteristics、Regulatory bodies、 Pricing、Reimbursement、the process of registering an innovative drug and generic drugs in Japan.
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Immuno-Oncology: Current Market Landscape and Future Trends（1） Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.